Anthem Biosciences IPO 2025: Powerful Update & Key Info

Anthem Biosciences IPO is a fully book-built issue and the total IPO size is ₹3,395.00 crores. The entire share offering is an offer for sale of ₹3,395.00 crores.

The dates for the Anthem Biosciences IPO are from 14 July 2025 to 16 July 2025.

The allotment process is expected to be finalized by 17 July 2025. The Anthem Biosciences IPOis scheduled to list on BSE and NSE, with a tentative listing date of 21 July 2025.

The price band for the Anthem Biosciences IPO is ₹540 to ₹570 per equity share.

Registrar for this IPO is KFin Technologies Limited and lead managers for Anthem Biosciences IPO are JM Financial Limited, Citigroup Global Markets India Private Limited, J.P. Morgan India Private Limited, Nomura Financial Advisory and Securities (India) Private Limited.

Explore more upcoming IPOs in India for comparison and investment planning.

IPO Schedule

IPO Open Date	Monday, 14 Jul, 2025
IPO Close Date	Wednesday, 16 Jul, 2025
IPO Allotment Date	Thursday, 17 Jul, 2025
Refund Initiation	Friday, 18 Jul, 2025
Share credit in Demat	Friday, 18 Jul, 2025
Listing Date	Monday, 21 Jul, 2025

Key Details

Price Band	₹540 to ₹570 Per Share
Lot Size	26 Shares
Face Value	₹2 Per Equity Share
Total Issue Size	₹339.50 Crores
Fresh Issue	-
OFS Issue	₹339.50 Crores
Employee Discount	₹50 Per Share
Issue Type	Offer for Sale
Listing At	BSE, NSE

Share Reservation

Investor Category	Shares Offered
QIB	50%
Retail	35%
NII/HNI	15%

Lot Size

Application	Lots	Shares	Amount
Retail (Min)	1	26	14,820
Retail (Max)	13	338	192,660
S-HNI (Min)	14	364	207,480
S-HNI (Max)	67	1742	992,940

About Anthem Biosciences Limited Company

Anthem BioSciences is an innovation-driven CRDMO (Contract Research, Development and Manufacturing Organization) serving global biotech and pharmaceutical companies. We stand out as one of the youngest and fastest-growing Indian CRDMOs, achieving ₹1,000 crore in revenue within 14 years. Our revenue growth from Fiscal 2023 to 2024 was the highest among our peers in India and globally.

Innovation drives our operations. We've developed platforms in areas like RNAi, ADCs, peptides, and oligonucleotides. We were pioneers in ADC development in India and are leveraging green chemistry techniques like biotransformation and flow chemistry to reduce waste and enhance cost efficiency. We are expanding manufacturing capabilities and adopting advanced technologies across different modalities.

Our services include CRDMO services and specialty ingredients. CRDMO spans from drug discovery to commercial manufacturing, with a strong presence in both small and large molecules. Our specialty ingredients business includes APIs, probiotics, enzymes, and more, sold in regulated and semi-regulated markets. For the six-month period ended September 30, 2024, CRDMO services accounted for 81.13% of our revenue from operations, and Specialty Ingredients accounted for 18.87% of our revenue from operations.

Anthem Biosciences Limited Financial Details

Period Ended	30 Sep 2024	30 Sep 2023	31 Mar 2024	31 Mar 2023	31 Mar 2022
Assets	2692.51	2351.38	2398.11	2014.46	1618.87
Revenue	910.85	623.17	1483.07	1133.99	1280.24
Profit After Tax	244.31	157.10	367.31	385.19	405.54
Net Worth	2204.37	1897.70	1924.66	1740.67	1355.00
Reserves and Surplus	2092.56	1783.60	1812.84	1626.57	1346.22
Total Borrowing	131.26	206.29	232.53	125.07	8.55

₹ In Crore

Key Performance Indicator

Basic EPS (in ₹)	Return on Net Worth (RoNW)	Net Asset Value (NAV)	Debt-Equity Ratio	Return on Equity (ROE)	Return on Capital Employed (ROCE)
6.48	20.03%	34.43	Data not Available	20.04%	25.71%

Offer Objectives

The Offer comprises an Offer for Sale (OFS) of equity shares by the Selling Shareholders aggregating up to ₹3,395 crore. The company will not receive any proceeds from the Offer; all proceeds will go to the Selling Shareholders after deducting offer-related expenses and relevant taxes, which will be borne by the respective Selling Shareholders. The objectives are to carry out the OFS and achieve the benefits of listing the equity shares on the stock exchanges, enhancing visibility, brand image, and providing liquidity.

Estimated offer expenses include fees for BRLMs, advertising, Registrar, SCSBs, Sponsor Banks, brokerage, printing, and other miscellaneous costs. The total estimated offer expenses are ₹[●] million. Expenses will be shared between the Company and Selling Shareholders, with the company initially making all payments and subsequently being reimbursed by the Selling Shareholders for their respective portions, only upon successful consummation of the transfer of the Offered Shares.

The company has implemented an Employee Stock Option Plan (ESOP 2024 Plan) to encourage employee ownership. As of the Draft Red Herring Prospectus date, 10,157,000 options were outstanding, and no options have been exercised. The exercise price of options is ₹100.75. Key Managerial Personnel (KMP) such as Divya Prasad and Mohammed Gawir Baig were granted 30,000 and 285,000 options respectively. The fair value of options was estimated using the Discounted Cash Flow (DCF) model with a risk-free interest rate of 7.05% and a weighted average cost of capital (WACC) of 15.93%. The fair value of the underlying equity share at the time of the grant was ₹134.31. The vesting period ranges from 1 to 4 years, with an exercise period of up to 5 years.